BioCentury
ARTICLE | Financial News

Genentech meets Street consensus, Idec will beat it

October 11, 2000 7:00 AM UTC

DNA reported third quarter EPS of $0.31, hitting the consensus Street estimate. The EPS number excludes $97.8 million in recurring charges related to the redemption of DNA special common stock by Roche (SWX:ROCZ) in 1999. Third quarter sales of Rituxan rituximab, an anti- CD20 antibody to treat non-Hodgkin's lymphoma licensed from IDPH, were $117.9 million, a 62 percent increase from $72.6 million in the 1999 quarter. Sales of Herceptin trastuzumab anti- HER2 antibody to treat breast cancer were $72.6 million, up 52 percent compared to $47.9 million in the 1999 quarter. ...